Literature DB >> 7353456

Rifampicin-induced elevation of serum bile acids in man.

R Galeazzi, I Lorenzini, F Orlandi.   

Abstract

Fasting and postprandial serum bile acid concentrations were determined by gas-liquid chromatography in 20 consecutive individuals (14 normal subjects, 6 cirrhotics) before and after administration of rifampicin in a single dose of 900 mg, using each individual as his own control. In the normal subjects the 2-hr postprandial level was 2.9 +/- 0.2 microM (mean +/- 1 SEM) prior to drug administration. Following rifampicin, it was 7.7 +/- 0.5 microM (P less than 0.0005). In the patients with liver cirrhosis the 2-hr postprandial level increased from 30.2 +/- 3.5 before, to 105.0 +/- 27.7 microM after rifampicin (P less than 0.025). Twelve hours after drug administration the levels of serum bile acids were not significantly different with respect to the control values. Total serum bilirubin also showed a transient and parallel increase. These findings are compatible with the hypothesis that rifampicin inhibits the hepatic transport of bile acids.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7353456     DOI: 10.1007/bf01308307

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  INITIAL DISTRIBUTION AND RATE OF UPTAKE OF SULFOBROMOPHTHALEIN IN THE LIVER.

Authors:  C A GORESKY
Journal:  Am J Physiol       Date:  1964-07

2.  Postprandial serum bile acids in healthy man. Evidence for differences in absorptive pattern between individual bile acids.

Authors:  B Angelin; I Björkhem
Journal:  Gut       Date:  1977-08       Impact factor: 23.059

3.  Bile acid excretion: the alternate pathway in the hamster.

Authors:  R Galeazzi; N B Javitt
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

4.  Plasma disappearance of radioactivity after intravenous injection of labeled bile acids in man.

Authors:  A E Cowen; M G Korman; A F Hofmann; P J Thomas
Journal:  Gastroenterology       Date:  1975-06       Impact factor: 22.682

5.  Postprandial serum bile acid for the detection of hepatobiliary disease.

Authors:  N Kaplowitz; E Kok; N B Javitt
Journal:  JAMA       Date:  1973-07-16       Impact factor: 56.272

6.  Quantitative estimation os bile salts in serum.

Authors:  S S Ali; N B Javitt
Journal:  Can J Biochem       Date:  1970-09

7.  Inhibition of hepatic uptake of bile acids by rifamycins.

Authors:  M S Anwer; R Kroker; D Hegner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-03       Impact factor: 3.000

8.  Two hepatic cytoplasmic protein fractions, Y and Z, and their possible role in the hepatic uptake of bilirubin, sulfobromophthalein, and other anions.

Authors:  A J Levi; Z Gatmaitan; I M Arias
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

9.  Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.

Authors:  G Acocella; L Bonollo; M Garimoldi; M Mainardi; L T Tenconi; F B Nicolis
Journal:  Gut       Date:  1972-01       Impact factor: 23.059

10.  Dynamics of the enterohepatic circulation of bile acids. Postprandial serum concentrations of conjugates of cholic acid in health, cholecystectomized patients, and patients with bile acid malabsorption.

Authors:  N F LaRusso; M G Korman; N E Hoffman; A F Hofmann
Journal:  N Engl J Med       Date:  1974-10-03       Impact factor: 91.245

View more
  11 in total

Review 1.  Hepatocellular transport proteins and their role in liver disease.

Authors:  C Stanca; D Jung; P J Meier; G A Kullak-Ublick
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

Review 2.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 3.  Pruritus associated with cholestasis. A review of pathogenesis and management.

Authors:  M Khandelwal; P F Malet
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

4.  Rifampicin and hepatic bile acid elimination.

Authors:  R Poupon
Journal:  Dig Dis Sci       Date:  1981-03       Impact factor: 3.199

5.  Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers.

Authors:  Issey Takehara; Hanano Terashima; Takeshi Nakayama; Takashi Yoshikado; Miwa Yoshida; Kenichi Furihata; Nobuaki Watanabe; Kazuya Maeda; Osamu Ando; Yuichi Sugiyama; Hiroyuki Kusuhara
Journal:  Pharm Res       Date:  2017-05-26       Impact factor: 4.200

6.  Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.

Authors:  M I Prince; A D Burt; D E J Jones
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 7.  The pregnane X receptor: from bench to bedside.

Authors:  Xiaochao Ma; Jeffrey R Idle; Frank J Gonzalez
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-07       Impact factor: 4.481

8.  Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity.

Authors:  MaryPeace McRae; Naser L Rezk; Arlene S Bridges; Amanda H Corbett; Hsiao-Chuan Tien; Kim L R Brouwer; Angela D M Kashuba
Journal:  Pharmacotherapy       Date:  2010-01       Impact factor: 4.705

9.  Compensatory Transition of Bile Acid Metabolism from Fecal Disposition of Secondary Bile Acids to Urinary Excretion of Primary Bile Acids Underlies Rifampicin-Induced Cholestasis in Beagle Dogs.

Authors:  LanLan Gui; QingLiang Wu; YiTing Hu; WuShuang Zeng; XianWen Tan; PingPing Zhu; XueJing Li; Lian Yang; Wei Jia; ChangXiao Liu; Ke Lan
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-22

10.  A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC Type 2 Patients.

Authors:  Vanessa Baier; Henrik Cordes; Christoph Thiel; José V Castell; Ulf P Neumann; Lars M Blank; Lars Kuepfer
Journal:  Front Physiol       Date:  2019-09-27       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.